Clinical Trial Update: Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of aflibercept monotherapy with DCE-US for chemorefractory metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: Barts & The London NHS Trust | Conditions: Colorectal Cancer | Phase 2 | Status: WITHDRAWN